Akashi Therapeutics   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2012)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2013
NCT01847573
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

AkashiTherapeutics | Askashi Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

halofuginone (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1